BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Sabestomig readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Sabestomig\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04541108-2091@assetmemo.bio
DTSTAMP:20261121T005443Z
DTSTART;VALUE=DATE:20311231
DTEND;VALUE=DATE:20320101
SUMMARY:Sabestomig: Phase 1 readout est. (NCT04541108)
DESCRIPTION:Sabestomig\, phase 1.\nStudy: Phase 0 Master Protocol for CIVO 
 Intratumoral Microdosing of Anti-Cancer Therapies\nEstimated primary compl
 etion: December 2031. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /sabestomig#upcoming-events\nRegistry record: https://clinicaltrials.gov/s
 tudy/NCT04541108
URL:https://assetmemo.bio/drug/sabestomig#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
